John Carey Net Worth

The estimated Net Worth of John F Carey is at least $2.35 Milion dollars as of 1 February 2023. Mr. Carey owns over 1,410 units of TransMedics stock worth over $2,233,369 and over the last 6 years he sold TMDX stock worth over $120,000. In addition, he makes $0 as Vice President - Operations at TransMedics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Carey TMDX stock SEC Form 4 insiders trading

John has made over 35 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,410 units of TMDX stock worth $23,801 on 1 February 2023.

The largest trade he's ever made was exercising 26,073 units of TransMedics stock on 1 December 2022 worth over $389,009. On average, John trades about 2,703 units every 30 days since 2019. As of 1 February 2023 he still owns at least 15,530 units of TransMedics stock.

You can see the complete history of Mr. Carey stock trades at the bottom of the page.

John Carey biography

John F. Carey serves as Vice President - Operations of the Company. He has been employed by us since February 2006 and has served as our Vice President of Operations since 2013. Prior to joining TransMedics, Mr. Carey held operations management positions at Vasca, Inc., a medical device company, from 1997 to 2006 and served as Vice President of Operations at Vasca from 2004 to 2006. Prior to joining Vasca, Mr. Carey held engineering and operations management positions at C. R. Bard, Inc. and Galileo Electro-Optics Corporation. Mr. Carey holds a Bachelor’s of Science degree in Mechanical Engineering from the University of Massachusetts.

How old is John Carey?

John Carey is 55, he's been the Vice President - Operations of TransMedics since 2013. There are 8 older and 7 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.

What's John Carey's mailing address?

John's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.

Insiders trading at TransMedics

Over the last 6 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein oraz James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.

What does TransMedics do?

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Complete history of Mr. Carey stock trades at TransMedics

TransMedics executives and stock owners

TransMedics executives and other stock owners filed with the SEC include:

• Waleed Hassanein,
  President, Chief Executive Officer, Director
• Tamer Khayal,
  Chief Commercial Officer
• Dr. Waleed H. Hassanein,
  Founder, MD, CEO, Pres & Director
• Dr. Tamer I. Khayal,
  Chief Commercial Officer
• Stephen Gordon,
  CFO. Treasurer & Sec.
• Stephen Gordon,
  Chief Financial Officer, Treasurer, Secretary
• David Weill,
  Independent Director
• James Tobin,
  Independent Chairman of the Board
• Thomas Gunderson,
  Independent Director
• Edward Basile,
  Independent Director
• Edwin Kania,
  Independent Director
• John Sullivan,
  Vice President - Quality and Engineering
• Miriam Provost,
  Vice President - Global Regulatory Affairs
• Laura Damme,
  Vice President - Clinical Affairs
• John Carey,
  Vice President - Operations
• Susan Goodman,
  VP of HR
• Mark Anderson,
  Sr. Director of Technology Devel.
• Ike Okonkwo,
  VP of Fin. & Accounting
• John F. Carey,
  VP of Operations
• Therapeutics Corp Lung Biot...,
  
• Ventures Fund Iv General Pa...,
  
• Capital Management, L.P.Abr...,
  
• Merilee Raines,
  
• Capital Management, L.P.Abr...,
  
• Rakesh P. Godhani,
  Chief Digital Officer
• Nicholas Corcoran,
  See Remarks
• Stephanie Lovell,
  
• Anil P. Ranganath,
  See remarks